A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis, with a commitment to address the substantial existing gaps in our knowledge and to help provide access to an effective cure and prophylaxis of drug-resistant tuberculosis throughout the world.
Nearly nine million people will develop tuberculosis (TB) in the world this year; at least 500,000 of these cases will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. Lacking a strong scientific basis in prescribing treatment regimens, existing TB treatments are often ineffective. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and, possibly, regimens involving new TB drugs, in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.
LIMITED ACCESS TO DELAMANID
UNDER COMPASSIONATE USE
This month, Nature Medicine reported on Otsuka’s compassionate use program of delamanid. Delamanid has been approved by regulators in Japan, South Korea and the European Medicines Agency. The drug is available on a limited basis in other countries through Otsuka’s compassonate use program; however, the company has refused to provide delamanid if it is in combination with bedaquiline. The company said combination of the two drugs could lead to a contraindication. Read the report in Nature Medicine here.
Doctors, whose patients need urgent access to delamanid, can send requests for compassionate use to email@example.com
RESIST-TB urges those who contact Otsuka to notify us of your experience at firstname.lastname@example.org
Recent News and Announcements
Médecins Sans Frontières (MSF), Treatment Action Campaign (TAC), Treatment Action Group (TAG) and others are calling on global health actors to step up and ensure new and repurposed DR-TB drugs reach people who are otherwise without treatment options. ** SIGN ON LETTER ** to global actors and drug companies New drugs to treat drug-resistant tuberculosis (DR-TB) […]
TB Alliance has announced the Phase I trial of TBA-354, the first TB drug to have advanced to Phase I trials in 6 years. Recruitment for the Phase I randomized, double-blind trial is under way. The trial plans to enroll 50 US volunteers and evaluate the safety, tolerability, pharmacokinetics, and dosing of TBA-354. In pre-clinical studies, […]
The recently published ECDC Annual Epidemiological Report on tuberculosis reported 3% of new cases and 19% of previously treated cases had MDR-TB among the 29 EU/EEA countries. MDR-TB in some countries remains high, with 11-20% of new pulmonary cases and 33-50% of previously treated cases reported in the three Baltic countries. Only 34% of MDR-TB cases […]
At the 45th World Conference on Lung Health, two new MDR-TB clinical trials were announced. The first, an expansion of the STREAM study called STREAM Stage 2 will compare a six-month bedaquiline containing regimen and a nine-month bedaquiline-containing regimen without an injectable to the current WHO standard of care and a modified Bangladesh regimen. STREAM […]
In a new report by the Review on Antimicrobial Resistance entitled “Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations,” characterized drug resistant TB as a “broad public health issue for which resistance is a concern.” Overall, the report estimates that failure to address drug resistant infections will cause 10 million deaths […]